Want to see GB:SUN full AI Analyst Report?
SUN Stock Chart & Stats
0.50 p
0.00 p(0.00%)
At close: 4:00 PM EDT
0.50 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range0.33 p - 0.74 p
Previous CloseN/A
Volume2.47K
Average Volume (3M)179.78K
Market Cap
£4.66M
Enterprise Value4.05 p
Total Cash (Recent Filing)£813.00K
Total Debt (Recent Filing)£665.00K
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Sep 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding932,816,160
10 Day Avg. Volume43,249
30 Day Avg. Volume179,777
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.55
Price to Sales (P/S)0.36
P/FCF Ratio8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageVery low debt and materially reduced total borrowings provide durable financial resilience. With limited leverage the company can absorb operating losses, fund near-term working capital, or selectively invest in product development or distribution without immediate refinancing risk, extending runway.
Improved Cash Generation In 2025The shift to positive operating and free cash flow in 2025 signals improving working-capital management and underlying cash conversion. Durable cash generation, even if modest, reduces dependence on external funding and supports incremental reinvestment in operations and commercialization over the medium term.
Recurring Demand From Consumables & InstrumentsA business model centered on consumables and reusable surgical instruments produces recurring revenue linked to procedure volumes and installed base. This structural demand supports predictable repeat sales, aids margin stability for consumables, and underpins long-term revenue durability versus one‑off product sales.
Bears Say
Revenue Softness And DeclineSustained flat-to-declining revenue constrains operating leverage and limits the ability to absorb fixed costs. Over months this hampers reinvestment in R&D, sales expansion, and margin recovery, and signals risks in market share, procedure volumes, or pricing competitiveness that could persist without strategic action.
Ongoing Losses And Margin PressureContinued negative operating profit and deteriorating gross margin erode shareholder equity and limit internally available funds for growth. Persistent losses reduce strategic flexibility, increase sensitivity to cost or reimbursement shifts, and necessitate either structural cost fixes or sustained margin improvement to reach lasting profitability.
Scale Limits And Cash VolatilityModest and volatile cash flows constrain capacity to scale sales, invest in commercialization, or withstand demand shocks. With a small operational scale and equity erosion noted historically, the company remains vulnerable to cyclical procedure volumes and faces execution risk when attempting to expand markets or product lines sustainably.
Surgical Innovations News
SUN FAQ
What was Surgical Innovations’s price range in the past 12 months?
Surgical Innovations lowest share price was 0.33 p and its highest was 0.74 p in the past 12 months.
What is Surgical Innovations’s market cap?
Surgical Innovations’s market cap is £4.66M.
When is Surgical Innovations’s upcoming earnings report date?
Surgical Innovations’s upcoming earnings report date is Sep 23, 2026 which is in 55 days.
How were Surgical Innovations’s earnings last quarter?
Surgical Innovations released its earnings results on Apr 21, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Surgical Innovations overvalued?
According to Wall Street analysts Surgical Innovations’s price is currently Overvalued.
Does Surgical Innovations pay dividends?
Surgical Innovations does not currently pay dividends.
What is Surgical Innovations’s EPS estimate?
Surgical Innovations’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Surgical Innovations have?
Surgical Innovations has 932,816,160 shares outstanding.
What happened to Surgical Innovations’s price movement after its last earnings report?
Surgical Innovations reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Surgical Innovations?
Currently, no hedge funds are holding shares in GB:SUN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Surgical Innovations
Established in 1988 and headquartered in Leeds, United Kingdom, Surgical Innovations Group plc is an international enterprise engaged in the design, development, manufacturing, and marketing of devices for minimally invasive surgery (SI) and precision engineering applications. Its global presence extends across the UK, Europe, the Asia Pacific region, and the United States. The company operates through three distinct divisions: SI Brand, Original Equipment Manufacturer (OEM), and Distribution. The SI Brand segment is responsible for the research, development, production, and commercialization of its proprietary SI-branded minimally invasive instruments. Key products within this portfolio include the YelloPort Elite and YelloPort +plus laparoscopic port access systems, LogiRange resposable laparoscopic instrument systems, FastClamp laparoscopic clamping systems, and QuickRange single-use laparoscopic instrumentation. The OEM division focuses on crafting and supplying minimally invasive devices for third-party medical device firms, often under their own brand or through co-branding arrangements. This segment also provides comprehensive design and development solutions for creating final medical devices and is involved in the research, development, manufacturing, and sale of minimally invasive technology tailored for precision engineering. Lastly, the Distribution segment handles the supply of various medical products, primarily via its subsidiary, Elemental Healthcare Ltd, and also designs and produces autologous blood products. Surgical Innovations Group plc sells its offerings through a network of independent healthcare distributors, while its own-label products are also distributed through its OEM collaborations.
Technical Analysis
Advanced Medical Solutions
―
Creo Medical
―
―
Smith & Nephew
―
TruSpine Technologies Plc
―








